نتایج جستجو برای: bedaquiline
تعداد نتایج: 462 فیلتر نتایج به سال:
Affiliations: Dept of Infectious Diseases, Galliera Hospital, Genova, Italy. Clinical Epidemiology and Medical Statistics Unit, Dept of Biomedical Sciences University of Sassari – Research, Medical Education and Professional Development Unit, AOU Sassari, Sassari, Italy. WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate, Italy. Public...
Over the last 10 years, interest in pediatric tuberculosis (TB) has increased dramatically, together with increased funding and research. We have a better understanding of the burden of childhood TB as well as a better idea of how to diagnose it. Our appreciation of pathophysiology is improved and with it investigators are beginning to consider pediatric TB as a heterogeneous entity, with diffe...
Bedaquiline, a diarylquinoline, improved cure rates when added to a multidrug-resistant tuberculosis (MDR-TB) treatment regimen in a previous placebo-controlled, phase 2 trial (TMC207-C208; NCT00449644). The current phase 2, multicenter, open-label, single-arm trial (TMC207-C209; NCT00910871) reported here was conducted to confirm the safety and efficacy of bedaquiline.Newly diagnosed or previo...
Bedaquiline (BDQ) is a novel and highly potent last-line antituberculosis drug that was approved by the US FDA in 2013. Owing to its stereo-structural complexity, chemical synthesis and compound optimization are rather difficult and expensive. This study describes the structural simplification of bedaquiline while preserving antitubercular activity. The compound's structure was split into fragm...
patient data meta-analysis. Eur Respir J 2013; 42: 169–179. 9 Migliori GB, De Iaco G, Besozzi G, et al. First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill 2007; 12: E070517.1. 10 Matteelli A, D’Ambrosio L, Centis R, et al. Compassionate and optimum use of new tuberculosis drugs. Lancet Infect Dis 2015; 15: 1131–1132. 11 World Health Organization. The use of delamanid...
Content/InfAZ/T/Tuberkulose/Download/TB2013.pdf?_blob=publicationFile Date last accessed: February 12, 2015. Date last updated: December 12, 2014. 7 World Health Oganization. The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance. Geneva, World Health Oganization, 2013. 8 Wolfson LJ, Walker A, Hettle R, et al. Cost-effectiveness of adding bedaquilin...
Drug tolerance likely represents an important barrier to tuberculosis treatment shortening. We previously implicated the Mycobacterium tuberculosis efflux pump Rv1258c as mediating macrophage-induced tolerance to rifampicin and intracellular growth. In this study, we infected the human macrophage-like cell line THP-1 with drug-sensitive and drug-resistant M. tuberculosis strains and found that ...
New regimens based on 2 or more novel agents are sought to shorten or to simplify treatment of tuberculosis (TB), including drug-resistant forms. Prior studies showed that the novel combinations of bedaquiline (BDQ) plus pretomanid (PMD) plus pyrazinamide (PZA) and PMD plus moxifloxacin (MXF) plus PZA shortened the treatment duration necessary to prevent relapse by 2 to 3 months and 1 to 2 mont...
BackgroundMultidrug-resistant tuberculosis (MDR-TB) patients have been suffering long, ineffective, and toxic treatment until short-course injectable-free regimens emerged. However, the new WHO-recommended might be less feasible in real-world setting. Here, we evaluated two optimized all-oral China.MethodsFrom April 2019 to August 2020, conducted a prospective nonrandomized controlled trial con...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید